Screener
Lexicon Pharmaceuticals LXRX Ratios & Valuation
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 99.1%0.0pp | 99.5%+1.5pp | 99.4%+1.4pp | 99.4%+5.9pp | 99.2%+6.7pp | |
| Operating margin | -131.4%+71.2pp | -34.8%+534pp | -98.2%+536pp | -94.4%+3,943pp | -202.6%+5,210pp | |
| Net margin | -147.4%+59.0pp | -37.5%+531pp | -101.1%+544pp | -96.8%+4,042pp | -206.4%+5,344pp | |
| Returns | ||||||
| Return on equity | -40.2%+25.1pp | -16%+70.1pp | -39.7%+128pp | -45.9%+90.2pp | -65.3%+29.5pp | |
| Return on invested capital | -32.7%+19.8pp | -13.5%+62.9pp | -33.5%+75.4pp | -37.5%+51.5pp | -52.5%+26.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.2×0.0× | 0.2×+0.2× | 0.2×+0.1× | 0.3×+0.3× | 0.2×+0.2× | |
| Liquidity | ||||||
| Current ratio | 13.4×+9.2× | 18.8×+16.6× | 4.9×-0.6× | 5.6×-1.8× | 4.2×-7.3× | |
| Leverage | ||||||
| Debt-to-equity | 0.3×-0.1× | 0.3×-0.6× | 0.6×-0.1× | 0.5×-0.1× | 0.5×0.0× | |
| Per Share | ||||||
| Book value per share | $0.40+12.0% | $0.51+49.1% | $0.30-35.0% | $0.33-33.0% | $0.36-53.9% | |
| Valuation | ||||||
| Market capitalization | $1.05B+151% | $660.94M+297% | $417.91M+56.5% | $490.59M-13.6% | $279.76M-53.9% | |
| Price / sales | 25.3×+18.1× | 9.5×+4.2× | 8.4×-0.2× | 6.9×-102× | 4.8×-162× | |
| Price / book | 6×+2.8× | 3.3×+1.9× | 3.9×+2.1× | 4.1×+0.9× | 2.2×-0.4× |
FAQ
- What are Lexicon Pharmaceuticals's profit margins?
- Lexicon Pharmaceuticals (LXRX) runs a 99.1% gross margin and a -131.4% operating margin, with a -147.4% net margin.
- Where do Lexicon Pharmaceuticals's ratios come from?
- Every ratio is computed from Lexicon Pharmaceuticals's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
